Menu
VJHemOnc Podcast
Podcast image
An update on menin inhibition in AML from iwAL 2024: current data, mechanisms of resistance, & more!
16 mins; October 23, 2024
An update on menin inhibition in AML from iwAL 2024: current data, mechanisms of resistance, & more!
16 mins; October 23, 2024
CAR T-cells and bispecific antibodies in the treatment of NHL: updates from iwNHL 2024
20 mins; October 15, 2024
CAR T-cells and bispecific antibodies in the treatment of NHL: updates from iwNHL 2024
20 mins; October 15, 2024
Prolonging remission in AML: current approaches & future outlooks
31 mins; October 08, 2024
Prolonging remission in AML: current approaches & future outlooks
31 mins; October 08, 2024
A focus on the use of artificial intelligence to personalize blood cancer care
28 mins; September 30, 2024
A focus on the use of artificial intelligence to personalize blood cancer care
28 mins; September 30, 2024
A focus on pediatric leukemias: trials, treatments, & challenges
17 mins; September 25, 2024
A focus on pediatric leukemias: trials, treatments, & challenges
17 mins; September 25, 2024
A focus on the psychosocial impacts of living with blood cancer
36 mins; September 18, 2024
A focus on the psychosocial impacts of living with blood cancer
36 mins; September 18, 2024
Global perspectives on blood cancers: addressing disparities in awareness, diagnosis, and treatment
18 mins; September 09, 2024
Global perspectives on blood cancers: addressing disparities in awareness, diagnosis, and treatment
18 mins; September 09, 2024
Insights into PV and ET: treating the AYA population, defining goals when treating patients, & more
11 mins; September 02, 2024
Insights into PV and ET: treating the AYA population, defining goals when treating patients, & more
11 mins; September 02, 2024
Hemophilia updates from ISTH 2024: ongoing clinical trials, emerging gene therapies & remaining challenges
18 mins; August 19, 2024
Hemophilia updates from ISTH 2024: ongoing clinical trials, emerging gene therapies & remaining challenges
18 mins; August 19, 2024
Inflammation and immune interventions in MDS: targeting STAT, IRAK4, & more
17 mins; August 12, 2024
Inflammation and immune interventions in MDS: targeting STAT, IRAK4, & more
17 mins; August 12, 2024
Updates in the treatment of SCD and thalassemia from EHA 2024: key trial updates, challenges with gene therapies & unmet needs
11 mins; August 05, 2024
Updates in the treatment of SCD and thalassemia from EHA 2024: key trial updates, challenges with gene therapies & unmet needs
11 mins; August 05, 2024
Unmet treatment needs in MF: managing prefibrotic disease & thrombocytopenia, novel agents & endpoints for clinical trials
16 mins; July 29, 2024
Unmet treatment needs in MF: managing prefibrotic disease & thrombocytopenia, novel agents & endpoints for clinical trials
16 mins; July 29, 2024
The role of BTK inhibitors in MCL, ongoing trials & future outlooks: updates from EHA 2024
12 mins; July 22, 2024
The role of BTK inhibitors in MCL, ongoing trials & future outlooks: updates from EHA 2024
12 mins; July 22, 2024
Novel developments in lower-risk MDS & important practical considerations when treating patients
51 mins; July 15, 2024
Novel developments in lower-risk MDS & important practical considerations when treating patients
51 mins; July 15, 2024
Updates on the use of BCMA-targeting bispecific antibodies in R/R multiple myeloma: insights from EHA & ASCO 2024
16 mins; July 08, 2024
Updates on the use of BCMA-targeting bispecific antibodies in R/R multiple myeloma: insights from EHA & ASCO 2024
16 mins; July 08, 2024
Updates in the treatment of CLL from EHA 2024: BTK and BCL2 inhibitor combinations, BTK degraders, and more
12 mins; July 01, 2024
Updates in the treatment of CLL from EHA 2024: BTK and BCL2 inhibitor combinations, BTK degraders, and more
12 mins; July 01, 2024
Highlights from ISA 2024: the importance of early diagnosis in AL amyloidosis, trials in progress & patient selection for SCT
8 mins; June 25, 2024
Highlights from ISA 2024: the importance of early diagnosis in AL amyloidosis, trials in progress & patient selection for SCT
8 mins; June 25, 2024
Treating LR-MDS beyond ESA failure: currently approved agents, novel approaches & future outlooks
46 mins; June 11, 2024
Treating LR-MDS beyond ESA failure: currently approved agents, novel approaches & future outlooks
46 mins; June 11, 2024
BPDCN treatment and management: CD123-targeting agents, CNS involvement & approaching pediatric/AYA patients
34 mins; June 03, 2024
BPDCN treatment and management: CD123-targeting agents, CNS involvement & approaching pediatric/AYA patients
34 mins; June 03, 2024
The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodies
12 mins; May 16, 2024
The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodies
12 mins; May 16, 2024
iwMyeloma 2024 Session I: approaching bone disease, clinical trial updates & the value of MRD as an endpoint in trials
27 mins; May 10, 2024
iwMyeloma 2024 Session I: approaching bone disease, clinical trial updates & the value of MRD as an endpoint in trials
27 mins; May 10, 2024
Managing anemia in MF, key emerging trials in the UK, and approaching young patients with MPNs
11 mins; May 03, 2024
Managing anemia in MF, key emerging trials in the UK, and approaching young patients with MPNs
11 mins; May 03, 2024
Highlights from EBMT 2024: treating & managing GvHD & understanding the role of the gut microbiome
22 mins; April 26, 2024
Highlights from EBMT 2024: treating & managing GvHD & understanding the role of the gut microbiome
22 mins; April 26, 2024
The importance of cardio-oncology: awareness around the ESC 2022 guidelines & the value of building MDTs
43 mins; April 11, 2024
The importance of cardio-oncology: awareness around the ESC 2022 guidelines & the value of building MDTs
43 mins; April 11, 2024
Exploring the possibility of early interception in smoldering myeloma: novel agents, challenges & advances in risk stratification
22 mins; April 04, 2024
Exploring the possibility of early interception in smoldering myeloma: novel agents, challenges & advances in risk stratification
22 mins; April 04, 2024
CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for approaching patients with myeloid precursors
13 mins; March 28, 2024
CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for approaching patients with myeloid precursors
13 mins; March 28, 2024
Monoclonal B-cell lymphocytosis: classification, biology and exploring the possibility of early interception
9 mins; March 22, 2024
Monoclonal B-cell lymphocytosis: classification, biology and exploring the possibility of early interception
9 mins; March 22, 2024
The impact of CAR-T therapy on the myeloma treatment landscape, patient selection for CAR-T & the evolving role of autoSCT
13 mins; March 15, 2024
The impact of CAR-T therapy on the myeloma treatment landscape, patient selection for CAR-T & the evolving role of autoSCT
13 mins; March 15, 2024
Diagnosing amyloidosis, currently available therapies & the importance of cardio-oncology
33 mins; March 07, 2024
Diagnosing amyloidosis, currently available therapies & the importance of cardio-oncology
33 mins; March 07, 2024
Addressing the importance of lymphodepletion, factors contributing to ICAHT & the cost effectiveness of CAR-T therapy
13 mins; February 29, 2024
Addressing the importance of lymphodepletion, factors contributing to ICAHT & the cost effectiveness of CAR-T therapy
13 mins; February 29, 2024
Updates with the use of CAR-T therapy in ALL: ongoing challenges, strategies to overcome resistance & future outlooks
12 mins; February 22, 2024
Updates with the use of CAR-T therapy in ALL: ongoing challenges, strategies to overcome resistance & future outlooks
12 mins; February 22, 2024
Targeted therapy in AML: the growing role of menin inhibitors & clinical trials exploring these agents
12 mins; February 16, 2024
Targeted therapy in AML: the growing role of menin inhibitors & clinical trials exploring these agents
12 mins; February 16, 2024
Updates in lower- and higher-risk MDS: challenges, novel agents & key clinical trials at ASH 2023
18 mins; February 08, 2024
Updates in lower- and higher-risk MDS: challenges, novel agents & key clinical trials at ASH 2023
18 mins; February 08, 2024
Key updates in thalassemia at ASH 2023: gene therapies, ongoing trials & the value of precision medicine
12 mins; January 31, 2024
Key updates in thalassemia at ASH 2023: gene therapies, ongoing trials & the value of precision medicine
12 mins; January 31, 2024
Updates, challenges and novel agents being explored in BPDCN
9 mins; January 25, 2024
Updates, challenges and novel agents being explored in BPDCN
9 mins; January 25, 2024
Unanswered questions regarding the sequencing of BCMA therapies, the prognostic value of CTCs & the growing role of quadruplets
18 mins; January 18, 2024
Unanswered questions regarding the sequencing of BCMA therapies, the prognostic value of CTCs & the growing role of quadruplets
18 mins; January 18, 2024
Key updates in sickle cell disease at ASH 2023: disease biology, ongoing trials & the growing role of gene therapy
11 mins; January 12, 2024
Key updates in sickle cell disease at ASH 2023: disease biology, ongoing trials & the growing role of gene therapy
11 mins; January 12, 2024
ASH 2023 highlights: updates in the diagnosis and treatment of amyloidosis
10 mins; January 05, 2024
ASH 2023 highlights: updates in the diagnosis and treatment of amyloidosis
10 mins; January 05, 2024
MPN highlights at ASH 2023: novel agents & ongoing clinical trials in ET, PV and MF
17 mins; December 22, 2023
MPN highlights at ASH 2023: novel agents & ongoing clinical trials in ET, PV and MF
17 mins; December 22, 2023
iwNHL 2023 Session V: Expanding the CAR platform in NHL
10 mins; December 15, 2023
iwNHL 2023 Session V: Expanding the CAR platform in NHL
10 mins; December 15, 2023
iwCLL 2023: The role of continuous BTKis, approaching Richter’s transformation & addressing the underrepresentation of elderly patients in trials
20 mins; December 07, 2023
iwCLL 2023: The role of continuous BTKis, approaching Richter’s transformation & addressing the underrepresentation of elderly patients in trials
20 mins; December 07, 2023
iwNHL 2023 Session IV: Novel therapies in NHL: BTK inhibitors, BTK degraders, and bispecific antibodies
15 mins; December 01, 2023
iwNHL 2023 Session IV: Novel therapies in NHL: BTK inhibitors, BTK degraders, and bispecific antibodies
15 mins; December 01, 2023
Unmet needs in AL amyloidosis, novel treatment strategies being explored, and the role of CHIP
12 mins; November 24, 2023
Unmet needs in AL amyloidosis, novel treatment strategies being explored, and the role of CHIP
12 mins; November 24, 2023
iwNHL 2023 Session III: Recent updates with the use of antibody-drug conjugates in NHL
16 mins; November 17, 2023
iwNHL 2023 Session III: Recent updates with the use of antibody-drug conjugates in NHL
16 mins; November 17, 2023
MPN diagnosis & treatment: novel agents in PV, clinical guidance for the use of JAK inhibitors & the growing role of combination approaches
12 mins; November 10, 2023
MPN diagnosis & treatment: novel agents in PV, clinical guidance for the use of JAK inhibitors & the growing role of combination approaches
12 mins; November 10, 2023
iwNHL 2023 Session II: The evolving treatment landscape in mantle cell lymphoma
14 mins; November 03, 2023
iwNHL 2023 Session II: The evolving treatment landscape in mantle cell lymphoma
14 mins; November 03, 2023
iwNHL 2023 Session I: Updates on the biology and treatment of T-cell lymphoma
13 mins; October 27, 2023
iwNHL 2023 Session I: Updates on the biology and treatment of T-cell lymphoma
13 mins; October 27, 2023
iwAL 2023 Session IV: Transplantation and immunotherapies in AML: improving patient outcomes
14 mins; October 20, 2023
iwAL 2023 Session IV: transplantation and immunotherapies in AML: improving patient outcomes
14 mins; October 20, 2023
Classifying frailty and approaching elderly patients with lymphoma
11 mins; October 13, 2023
Classifying frailty and approaching elderly patients with lymphoma
11 mins; October 13, 2023
Updates on the diagnosis, risk stratification and treatment of lower-risk MDS
19 mins; October 06, 2023
Updates on the diagnosis, risk stratification and treatment of lower-risk MDS
19 mins; October 06, 2023
Click here to see more
Useful pages

Apply to teach

Reviews

Help & FAQs

Blog

Spanish Podcast

French Podcast

Italian Podcast

About Us

Contact Us

Terms & Privacy

Find a tutor

Arabic tutors

Chinese tutors

Dutch tutors

English tutors

French tutors

German tutors

Greek tutors

Italian tutors

Japanese tutors

Korean tutors

Portuguese tutors

Romanian tutors

Russian tutors

Spanish tutors

Swedish tutors

Thai tutors

More languages soon!

Languages

Learn Arabic

Learn Chinese

Learn Dutch

Learn English

Learn French

Learn German

Learn Greek

Learn Italian

Learn Japanese

Learn Korean

Learn Portuguese

Learn Romanian

Learn Russian

Learn Spanish

Learn Swedish

Learn Thai

© 2026 LanguaTalk, All Rights Reserved